Current Seminars
01/12/2020 - 18:15 -
Biopartnering Seminar Series - Cosentyx Seminar - By: Team Poseidon Consulting Group
Abstract: Plaque psoriasis (PsO) is a chronic auto-inflammatory condition that exhibits as itchy, red, scaly patches on the skin and is estimated to impact approximately 2% of the population. Although a majority of cases are mild, the moderate-to-severe cases can be debilitating to many and yield a variety of comorbidities due to the...
24/11/2020 - 19:30 -
Biopartnering Seminar Series - Aducanumab - By Team 99
Abstract: Polygenic risk scores (PRS), derived from genome-wide association studies (GWAS), are an up and coming tool in precision/personalized medicine. How might they be leveraged by Biogen, who has just filed a BLA for Aducanumab, a monoclonal antibody (mAb) for the treatment for Alzheimer’s disease?
Alzheimer’s disease (AD) is a...
24/11/2020 - 18:15 -
Biopartnering Seminar Series - Orencia: Making it Personal - By Proche Solutions
Abstract: Rheumatoid Arthritis (RA) is a chronic, highly heterogeneous autoimmune condition characterized by inflammation of synovial joints with a prevalence of 0.5-1% and an incidence of 41 per 100,000 annually. Bristol-Myers Squibb (BMS)’s Orencia (abatacept) is a IgG1/CTLA-4 fusion protein that blocks T cell activation and is indicated...
17/11/2020 - 19:15 -
Biopartnering Seminar Series - "Dex" - By Future Digital Agents
Abstract: Alzheimer’s Disease (AD) and related dementia affects 50 million people worldwide, with 5.8 million Americans currently diagnosed with AD and cases expected to reach 14 million by 2050. Agitation is the one of the most commonly reported symptoms (up to 70% of dementia cases), leading to heightened caregiver stress,...
17/11/2020 - 18:15 -
Biopartnering Seminar Series - Applications of a COVID-19 Human Challenge Trial in Canada: Looking into Suitable Vaccine Candidates - By Fea5ible Pharma
Abstract: COVID-19 emerged in December of 2019, and has since severely impacted the way of life globally. The negative health and economic implications of this virus have initiated a global race towards a vaccine. There are approximately 200 vaccine candidates, 11 of which have already entered Phase III clinical trials. Vaccine development takes...